non-small cell lung cancer
Conditions
Interventions
treatment group:Intercostal artery infusion chemotherapy combined with bronchial artery embolization
Sponsors
PLA 309th Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) aged 18-75 years, gender not limited; (2) histopathological diagnosis of lung adenocarcinoma and squamous cell carcinoma of live small cell lung cancer; (3) TNM stage is IIIB or IV A; (4) have 1 or more measurable lesions according to RECIST1.1 standard; (5) refusal of chemotherapy or poor effect after chemotherapy; (6) ECOG score of physical fitness 6 months; (8) signed the consent of treatment protocol.
Exclusion criteria
Exclusion criteria: (1) patients with extensive uncontrolled extra-pulmonary metastases; (2) patients with mutations in gene detection can be treated with targeted drugs; (3) patients who have had or are currently experiencing other malignancies (except for cured basal or squamous cell skin cancer or carcinoma in situ of the cervix); (4) leukocyte 2mg/L; Twice the normal upper limit of AST and/or ALT >); (6) coagulation dysfunction (INR > 1.5) or known bleeding disease, or anticoagulant therapy; (7) patients with combined active infection requiring antibiotic treatment; (8) uncontrollable hypertension, diabetes, cardiovascular disease with obvious symptoms and a large amount of hydrothorax; (9) death due to unsuccessful embolization or non-study related factors; (10) hypersensitivity to contrast agents; (11) women with combined pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Partial remission rate;progression of disease;Overall survival rate; | — |
Countries
China
Contacts
Public ContactWeiguo Zhao
PLA 309th Hospital
Outcome results
None listed